Lipid lowering and beyond: Results from the CARE study on lipoproteins and inflammation

Herz

Volumn 24, Issue 1, 1999, Pages 51-56

  Sacks, Frank M ^a   Ridker, Paul M ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b NONE

Author keywords

CARE; Cholesterol; CRP; Inflammation; LDL; Lipoproteins; SAA

Indexed keywords

AMYLOID A PROTEIN; C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ANTIINFLAMMATORY ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR;

EID: 0033033161     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03043818     Document Type: Review

References (16)

1. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
2. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results. II. The relationship of reduction of incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-74.
3. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641-51.
4. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol 1998;31:1460-5.
5. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and risks of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
6. Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998;97:425-8.
7. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-3.
8. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998;9:839-44.
9. Sacks FM, Pfeffer MA, Moye L, et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction. The Cholesterol and Recurrent Events Trial (CARE). Am J Cardiol 1991;68:1436-46.
10. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
11. Sacks FM, Moye LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998;97:1446-52.
12. Scandinavian Simvastatin Survival Study Group (4S). Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
13. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
14. Vaughan CJ, Murphy MB. Buckley BM. Statins do more than just lower cholesterol. Lancet 1996;348:1079-82.
15. Shiomi M, Ito T, Tsukada T, et al. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques: effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Atheroscler Thromb Vasc Biol 1995;15:1938-44.
16. Williams JK, Sukhova GK, Herrington DM, et al. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998;31:684-91.